These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 657108

  • 81. Intralesional Bacillus Calmette-Guérin immunotherapy of canine venereal tumors.
    Hess AD, Catchatourian R, Zander AR, Epstein RB.
    Cancer Res; 1977 Nov; 37(11):3990-4. PubMed ID: 143344
    [Abstract] [Full Text] [Related]

  • 82.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 83.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 84. Use of maintenance intravesical bacillus Calmette-Guérin (BCG), with or without intradermal BCG, in patients with recurrent superficial bladder cancer. Long-term follow-up of a randomized phase 2 study.
    Witjes JA, Fransen MP, van der Meijden AP, Doesburg WH, Debruyne FM.
    Urol Int; 1993 Nov; 51(2):67-72. PubMed ID: 8351757
    [Abstract] [Full Text] [Related]

  • 85. Sequential evaluation of general immune competence in cancer patients: correlation with clinical course.
    Eilber FR, Nizze JA, Morton DL.
    Cancer; 1975 Mar; 35(3):660-5. PubMed ID: 234294
    [Abstract] [Full Text] [Related]

  • 86. Successful transurethral intralesional BCG therapy of a bladder melanoma.
    deKernion JB, Golub SH, Gupta RK, Silverstein M, Morton DL.
    Cancer; 1975 Nov; 36(5):1662-7. PubMed ID: 1192356
    [Abstract] [Full Text] [Related]

  • 87.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 88.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 89.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 90. Effect of administration of BCG, levamisole and irradiated leukemic cells on immune status and remission status in chronic myelogenous leukemia.
    Advani SH, Gulwani B, Ghogale SG, Shetye MR, Gangal SG.
    Oncology; 1985 Nov; 42(5):275-81. PubMed ID: 3897932
    [Abstract] [Full Text] [Related]

  • 91. Tests of cell mediated immunity in patients with early breast cancer. I. Response to DNCB at time of mastectomy.
    Davies CJ, Meredith ID, Robins RA, Blamey RW, Baldwin RW.
    Clin Oncol; 1978 Sep; 4(3):227-34. PubMed ID: 750125
    [No Abstract] [Full Text] [Related]

  • 92.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 93.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 94. Experience with BCG adjuvant immunotherapy in stage II malignant melanoma.
    Peter HH, Deutschmann EM, Schultheis W, Deicher H.
    Dev Biol Stand; 1978 Sep; 38():537-40. PubMed ID: 344106
    [Abstract] [Full Text] [Related]

  • 95. Immunotherapy of human malignant melanoma with irradiated tumor cells, oral Bacillus Calmette-Guérin, and levamisole.
    Shibata HR, Jerry LM, Lewis MG, Mansell PW, Capek A, Marquis G.
    Ann N Y Acad Sci; 1976 Sep; 277(00):355-66. PubMed ID: 1069555
    [No Abstract] [Full Text] [Related]

  • 96. Efficacy and tolerance of one-third full dose bacillus Calmette-Guérin maintenance therapy every 3 months or 6 months: two-year results of URO-BCG-4 multicenter study.
    Pfister C, Kerkeni W, Rigaud J, Le Gal S, Saint F, Colombel M, Guy L, Wallerand H, Irani J, Soulie M, Cancer Committee of French Urological Association.
    Int J Urol; 2015 Jan; 22(1):53-60. PubMed ID: 25256813
    [Abstract] [Full Text] [Related]

  • 97. A prospective study of immune responsiveness in human melanoma. I. Assessment of initial pretreatment status with stage of disease.
    Pritchard DJ, Ritts RE, Taylor WF, Miller GC.
    Cancer; 1978 Jun; 41(6):2165-73. PubMed ID: 306870
    [Abstract] [Full Text] [Related]

  • 98. Malignant melanoma. Delayed hypersensitivity skin testing.
    Roses DF, Campion JF, Harris MN, Gumport SL.
    Arch Surg; 1979 Jan; 114(1):35-8. PubMed ID: 758875
    [Abstract] [Full Text] [Related]

  • 99. The significance of conversion of skin reactivity to efficacy of bacillus Calmette-Guérin (BCG) vaccinations given immediately after radical surgery in stage II melanoma patients.
    Cascinelli N, Rümke P, MacKie R, Morabito A, Bufalino R.
    Cancer Immunol Immunother; 1989 Jan; 28(4):282-6. PubMed ID: 2702680
    [Abstract] [Full Text] [Related]

  • 100. Chemoimmunotherapy for metastatic malignant melanoma using vincristine (NSC-67574), DTIC (NSC-45388) and Bacillus Calmette-Guerin.
    Thatcher N, Blackledge G, Palmer MK, Crowther D.
    Eur J Cancer (1965); 1981 Apr; 17(4):465-9. PubMed ID: 7308256
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.